8-K: Certara Q3 2025 Revenue Up 10%, Raises Profit Targets

Certara, Inc. reported a 10% increase in third-quarter 2025 revenue to $104.6 million, driven by strong software growth, and updated its full-year 2025 financial guidance, raising profitability targets.

Summary

• Total revenue for the third quarter of 2025 was $104.6 million, representing year-over-year growth of 10% from $94.8 million in Q3 2024.
• Software revenue grew 22% year-over-year to $43.8 million, with organic software revenue growth of 6%.
• Services revenue increased 3% year-over-year to $60.8 million.
• Net income for Q3 2025 was $1.5 million, a significant improvement from a net loss of $1.4 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $35.2 million, up 7% from $33.1 million in Q3 2024.
• Diluted earnings per share was $0.01, compared to a diluted loss per share of $(0.01) in Q3 2024.
• Adjusted diluted earnings per share was $0.14, flat compared to $0.13 in Q3 2024.
• Total Bookings for Q3 2025 were $96.6 million, a 1% year-over-year increase.
• Software Bookings grew 17% year-over-year to $40.8 million, with organic software bookings up 5%.
• Services Bookings decreased 9% year-over-year to $55.8 million, primarily due to softer trends in Regulatory services.
• Full-year 2025 revenue guidance was narrowed to a range of $415 million to $420 million.
• Full-year 2025 adjusted EBITDA margin guidance was raised to approximately 32%.
• Full-year 2025 adjusted diluted earnings per share guidance was raised to a range of $0.45 $0.47.

Sentiment

Score: 7

Explanation: The company delivered solid top-line growth, particularly in its high-margin software segment, and successfully transitioned from a net loss to net income. The upward revision of full-year profitability targets signals management's confidence. However, the decline in services bookings and noted spending hesitancy in parts of the services business introduce a degree of caution, preventing a higher sentiment score.

Positives

• Strong overall revenue growth of 10% year-over-year, reaching $104.6 million.
• Significant software revenue growth of 22% year-over-year, demonstrating robust demand for biosimulation solutions.
• Return to net income of $1.5 million in Q3 2025, compared to a net loss of $1.4 million in the prior year.
• Adjusted EBITDA increased by 7% year-over-year to $35.2 million.
• Raised full-year 2025 profitability targets for Adjusted EBITDA margin (to ~32%) and Adjusted Diluted EPS (to $0.45 $0.47).
• Successful launch of new software products, including CertaraIQ for QSP modeling, expected to expand market reach.

Negatives

• Services bookings decreased by 9% year-over-year to $55.8 million.
• Observed spending hesitancy in certain parts of the services business, particularly in Regulatory services among tier-one customers.
• Cash and cash equivalents decreased to $172.7 million as of September 30, 2025, from $233.0 million at September 30, 2024.

Risks

• Any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development.
• Ability to compete effectively within the market.
• Changes or delays in government regulation relating to the biopharmaceutical industry.
• Trends in research and development (R&D) spending.
• Consolidation within the biopharmaceutical industry and a shift toward more R&D occurring at smaller biotechnology companies.
• Failure of existing customers to renew software licenses or any delays, terminations of contracts, or reductions in scope of work.
• Risks related to the use of artificial intelligence and machine learning in products and services.
• Any unauthorized access to or use of customer or other proprietary or confidential data or other breach of cybersecurity measures.

Future Outlook

Certara updated its full-year 2025 guidance, narrowing revenue expectations to a range of $415 million to $420 million. The company raised its full-year adjusted EBITDA margin target to approximately 32% and its adjusted diluted earnings per share to a range of $0.45 $0.47. Fully diluted shares are expected to be between 160 million and 162 million.

Management Comments

• "We continued to make good progress towards our full-year revenue and profitability targets." William Feehery, Chief Executive Officer.
• "We recently launched several new software products, including CertaraIQ for QSP modeling, which we believe will expand the use of biosimulation technology in drug development." William Feehery, Chief Executive Officer.
• "We remain focused on investing in our R&D and commercial efforts to position Certara for sustainable, long-term growth." William Feehery, Chief Executive Officer.
• "We saw strong demand in the quarter for biosimulation solutions in software and QSP services, though we have observed some spending hesitancy in other parts of the services business." John Gallagher, Chief Financial Officer.
• "We are raising our 2025 profitability targets and narrowing our revenue guidance to reflect the most likely range of outcomes as we approach the end of the year." John Gallagher, Chief Financial Officer.

Industry Context

Certara operates in the biopharmaceutical industry, providing model-informed drug development solutions. The strong demand for biosimulation software and QSP services aligns with the industry's increasing adoption of advanced computational methods to accelerate drug discovery and development. However, observed spending hesitancy in other services areas, particularly regulatory services and among tier-one customers, suggests potential broader economic pressures or shifts in R&D outsourcing strategies within the pharmaceutical sector.

Legal Proceedings

• The company incurred $246 thousand in litigation and settlement expense for Q3 2025, related to a non-recurring employment litigation and settlement outside the normal course of business.
• Risks related to litigation against the company are noted in forward-looking statements.

Stakeholder Impact

• Shareholders: Benefited from the return to net income, 10% revenue growth, and raised profitability guidance. However, a 9% decrease in services bookings and a reduction in cash and cash equivalents could be areas of concern.
• Employees: Employee-related costs increased, and equity-based compensation is a significant part of the compensation strategy, indicating continued investment in the workforce. The company also noted risks related to retaining key personnel.
• Customers: Strong demand for biosimulation software and QSP services. However, some tier-one customers exhibited spending hesitancy in regulatory services, potentially impacting future service engagements.
• Creditors: The company continues to manage its long-term debt, with payments made, but the overall debt level remains a factor.

Next Steps

• Host a conference call on November 6, 2025, at 5:00 p.m. ET to discuss third-quarter 2025 financial results.
• Continue investing in R&D and commercial efforts to position Certara for sustainable, long-term growth.
• Monitor the Investor Relations section of the company website for material, non-public information and Regulation FD compliance.

Key Dates

Recommendation

While Certara demonstrated strong software revenue growth and a return to net profitability, along with raised profitability guidance, the decline in services bookings and observed spending hesitancy in certain service areas introduce a degree of uncertainty. The company's core biosimulation business remains robust, but the mixed performance across segments warrants a cautious 'hold' recommendation. Investors should monitor the services segment's recovery and the impact of new product launches on overall growth.

Keywords

Certara, CERT, Q3 2025 Earnings, Financial Results, Biosimulation, Drug Development, Software Revenue, Adjusted EBITDA, Financial Guidance, SEC Filing, Pharmaceutical Technology, Life Sciences Software